PYC — PYC Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- AU$339.69m
- AU$315.60m
- AU$15.89m
- 41
- 17
- 90
- 50
2019 June 30th | C2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 2.6 | 3.18 | 16.1 | 15.9 |
Cost of Revenue | |||||
Gross Profit | -1.84 | — | — | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7.1 | 9.64 | 21.8 | 30.3 | 39.2 |
Operating Profit | -7.1 | -7.04 | -18.6 | -14.3 | -23.3 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -6.98 | -7.08 | -18.6 | -14.3 | -23.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.08 | -7.08 | -18.6 | -14.3 | -23.4 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -4.08 | -6.82 | -17.8 | -13.9 | -22.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.08 | -6.82 | -17.8 | -13.9 | -22.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.002 | -0.003 | -0.006 | -0.004 | -0.007 |